-
2 months ago | 
academic.oup.com | Carolyn S P |van Veldhuisen
An expansion of fat mass is an integral feature of patients with heart failure and preserved ejection fraction (HFpEF). While body mass index (BMI) is the most common anthropometric measure, a measure of central adiposity—the waist-to-height ratio (WHtR)—focuses on body fat content and distribution; is not distorted by bone or muscle mass, sex, or ethnicity; and may be particularly relevant in HFpEF.
-
Jan 13, 2025 | 
eprints.gla.ac.uk | Carolyn S P |John V
Butt, J. H. et al. (2025) Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. Lancet Diabetes and Endocrinology, (doi: 10.1016/S2213-8587(24)00309-7) (In Press)Text345134.pdf - Published Version Available under License Creative Commons Attribution. 1MBAbstractBackground: Data on the effect of mineralocorticoid receptor antagonist therapy on HbA1c levels and new-onset diabetes are conflicting.
-
Jan 7, 2025 | 
eprints.gla.ac.uk | Carolyn S P |van Veldhuisen
Solano, S. et al. (2025) Clinical characteristics and outcomes of patients with heart failure with preserved ejection fraction and with reduced ejection fraction according to the prognostic nutritional index: findings from PARADIGM‐HF and PARAGON‐HF. Journal of the American Heart Association, 14(1), e037782. (doi: 10.1161/JAHA.124.037782) (PMID:39719408) Text343856.pdf - Published Version Available under License Creative Commons Attribution Non-commercial.
-
Nov 29, 2024 | 
academic.oup.com | Université de Lorraine |CHRU Nancy Brabois |Carolyn S P
Recent advances have given rise to a spectrum of digital health technologies that have the potential to revolutionize the design and conduct of cardiovascular clinical trials.
-
Nov 28, 2024 | 
link.springer.com | Garcia Sanchez |Juan Jose |Carolyn S P
AbstractReal-world data from patients with chronic kidney disease (CKD) are limited, particularly regarding clinical management, treatment patterns and health-related quality of life (HRQoL) in the context of new therapies and updated standard of care guidelines.
-
Aug 1, 2024 | 
cardiab.biomedcentral.com | Del Prato |Carolyn S P |Baylor Scott
The ARISE-HF trial (NCT 04083339; Date Registered August 23, 2019) is an ongoing phase 3 randomized, placebo-controlled, double-blinded clinical trial that aims to investigate the efficacy of AT-001, an aldose reductase inhibitor, in patients with DbCM, with any prior history of overt HF. All patients provided written, informed consent. All study procedures were approved by individual Institutional Review Boards and the study was conducted in accordance with the Declaration of Helsinki.
-
Nov 30, 2023 | 
eprints.gla.ac.uk | Joao Pedro |John F |John J. V |Carolyn S P
Monzo, L. et al. (2023) High risk of stroke in patients with worsening heart failure, reduced ejection fraction, coronary heart disease and sinus rhythm: risk prediction score analysis from the COMMANDER-HF trial. Journal of Cardiac Failure, (Accepted for Publication)Text310206.pdf - Accepted Version Restricted to Repository staff only Available under License Creative Commons Attribution Non-commercial No Derivatives.
-
Nov 28, 2023 | 
eprints.gla.ac.uk | De Boer |Carolyn S P |John V
Chatur, S. et al. (2023) Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial. Circulation, 148(22), pp. 1735-1745. (doi: 10.1161/circulationaha.123.066506) (PMID:37632455) (PMCID:PMC10664793) Text310264.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives.
-
Sep 28, 2023 | 
eprints.gla.ac.uk | Zi Michael |Carolyn S P |De Boer |Anna Maria
Bhatt, A. S. et al. (2023) Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3043) (PMID:37771274) (Early Online Publication)Text307595.pdf - Accepted Version Restricted to Repository staff only until 28 September 2024. 486kBAbstractIntroduction:COVID-19 may affect clinical risk in patients with heart failure.
-
Sep 5, 2023 | 
eprints.gla.ac.uk | Carolyn S P |De Boer |Anna Maria |John V
Kondo, T. et al. (2023) Efficacy of dapagliflozin according to geographic location of patients with heart failure. Journal of the American College of Cardiology, 82(10), pp. 1014-1026. (doi: 10.1016/j.jacc.2023.05.056) (PMID:37610398) Text310325.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives.
